Swine Vaccines Market By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, Recombinant Vaccines), By Disease Target (Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), Classical Swine Fever (CSF), Foot and Mouth Disease (FMD), Swine Influenza, Mycoplasma Hyopneumoniae, Others), By Route of Administration (Intramuscular, Subcutaneous, Intranasal, Oral), By Application (Commodity Pigs, Breeding Pigs), By Distribution Channel (Veterinary Hospitals & Clinics, Veterinary Pharmacies, Online Pharmacies, Government Tenders, Market Sales), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles and Market Forecast, 2025 – 2035

---

What trends will shape this market in the coming years?

The Swine Vaccines Market accounted for USD 1.81 Billion in 2024 and USD 1.91 Billion in 2025 is expected to reach USD 3.30 Billion by 2035, growing at a CAGR of around 5.62% between 2025 and 2035. Swine vaccines are biological preparations designed to protect pigs (swine) from various infectious diseases caused by bacteria, viruses, and parasites. Numerous vaccines are employed to guard pigs against diseases that have the potential to adversely affect their health, labour productivity and overall pig farming income. The vaccines enable the animals to resist general viruses, bacteria and other infectious organisms which are common in variations in swine like PRRS, PCV2 and swine "flu." Swine vaccines are on the rise due to concerns about animal health, food safety and the economic impact of disease on pig farms. Increased success in veterinary science and increased vigilance on the part of farmers result in reduced usage of antibiotics and stable vaccines to enhance herd immunity against disease. Government assistance for disease control and increased commercial pig farming are both drivers contributing to growth in the swine vaccines market globally.

What do industry experts say about the market trends?

“Vaccinated pigs will be challenged using a virulent ASF virus strain in a model developed recently at Pirbright to mimic natural routes of infection, offering exciting potential for vaccine development.”

• Dr. Chris Netherton – Head of African Swine Fever Vaccinology Group, The Pirbright Institute

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the market?

Rising outbreaks of swine-related diseases such as African swine fever and PRRS are increasing the demand for preventive vaccination.

The spread of diseases such as ASF and PPRS in pigs is increasing, and thus pig farms are in dire need of methods to prevent them. The prevalence of the diseases has adverse economic impacts in terms of reducing productivity, resulting in increased fatalities and changing the pork supply. Because there is no vaccine to prevent ASF, the disease has made farmers, veterinarians and governments more interested in the prevention of such incidences. For such conditions as PRRS and classical swine fever, vaccination is being encouraged more and more, since effective vaccines already exist against them. Being disease-prevention vaccines, these are being employed more and more in general herd health programs.

The majority of Asia and Europe pig-raising countries have imposed stricter biosecurity laws and invested in pig health services after outbreaks of recent diseases. Some additional farmers are willing to implement overall vaccination programs to protect their animals and avoid losses. New strains and evolving pathogens are pressurizing researchers to develop better vaccines. In a bid to control epidemics of disease in regions with huge herds of animals kept in close vicinity to one another, governments are investing in immunization programs and teaming up with private firms. Due to this, the growth in the number of swine diseases is accelerating the use of vaccines and increasing the global demand for swine vaccines.

Growing awareness among farmers about animal health and productivity promotes higher adoption of veterinary vaccines.

The increase in farmers' knowledge regarding how disease prevention in animals and animal health affects their swine productivity has been one of the principal causes for the expansion of the market for swine vaccines. Due to more commercialized livestock farming and stiff competition, numerous farmers now realize that keeping their pigs healthy will contribute to them realizing better growth, more breeding and fewer fatalities. Due to this shift in thinking, most pet owners now choose to get vaccinated regularly. Greater awareness regarding vaccination was brought through awareness campaigns, government-operated programs and also with the assistance of veterinarians.

Farmers have also come to understand that certain diseases like PRRS, PCV2 and swine flu, may impact a herd's productivity without presenting any apparent signs, leading to loss of revenue. That is why they prefer to include vaccines in their overall prevention plan against animal diseases instead of turning to them only when the need arises. The ease of giving vaccines and combined vaccines that require fewer shots has simplified the process of vaccination for more individuals. In regions covered by government livestock projects, farmers now have knowledge which benefits the market for swine vaccines to excel.

High vaccine development costs and storage limit accessibility for small-scale or rural pig farmers.

Creating effective vaccines can be very expensive, so this is a big problem for small-scale and rural farmers raising pigs. Creating a vaccine takes considerable time and resources, and involves much research, multiple stages of testing, adherence to regulations and preparing production facilities. Because these expenses are included in the vaccines’ sale price, they can be too expensive for farmers on a tight budget. Those managing tight funds may not put much importance on vaccines if there is currently no disease outbreak. This leads to many farmers worldwide skipping vaccination.

There is a problem with how swine vaccines should be handled, as they generally need to be cooled and kept in constant conditions. In places where electricity and cold chain services are unreliable or do not exist, it is very difficult to ensure vaccines remain potent. This results in fewer farmers and veterinary workers using vaccines because they run the risk of vaccine spoilage and reduced effectiveness. Since there are few people available who can properly manage vaccines in these situations, the issue becomes even more complex. Being costly and difficult to supply are important barriers to the adoption of swine vaccines by underserved communities.

Advancements in recombinant and DNA-based vaccine technologies create the potential for more efficient and targeted swine vaccines.

Technological advancements in the production of vaccines through the utilization of recombinant and DNA methods are opening a vast array of new possibilities in the swine vaccine market. Through sophisticated vaccine platforms, scientists can produce antigens to boost the immune system of swine without the need to utilize harmful pathogens. Vaccines based on recombinant technology can be designed to combat certain strains of viruses and bacteria and therefore improve immunity against developing swine diseases such as PRRS or PCV2. By using DNA technology, the pig cells themselves are triggered to produce the antigen required, so that the immune system has a more sustained defence. Because of these new technologies, manufacturers can react far more swiftly when there is an outbreak.

New vaccine types are more stable and easier to implement, lessening the strain on the individuals responsible for vaccinating large numbers of animals. As additional R&D is finalized, newer generation vaccines become more marketable, especially in nations that have strict farm and animal control policies. With the increase in time, as such technologies become more affordable and more individuals become aware of them, they will tend to emerge in developing countries and deliver innovation advancement, disease management, and pig health protection. This change in technology helps companies and governments to change their pig vaccination strategies, increase herd immunity and achieve a stable supply of safe food.

The expansion of commercial pig farming in emerging economies provides a largely untapped market for swine vaccine manufacturers.

There is a huge opportunity for manufacturers of swine vaccines to supply their products to the growing numbers of commercial pig farms in developing nations. Due to the shift in Asia, Latin America and Africa away from small-scale backyard farms to larger industrial operations, maintaining herd health is becoming increasingly crucial. Because the animals are in closer proximity to one another in these growing farms, it is essential to utilize vaccinations to avoid disease. Here, both the government and farming organizations are promoting the employment of current immunization schemes to improve productivity and quality of food.

The shift makes companies that manufacture vaccines capable of customizing their products according to the specific demands of a given region. When commercial pig farming generates a greater profit, farmers are quick to invest money in health care to protect their pigs from illness and death. International manufacturers can work with local organizations, veterinarian institutions and policymakers to enhance the vaccine administration in the animals. As infrastructure and delivery in these markets is improved, demand for swine vaccines will increase as individuals seek sustainable means of maintaining animals' health.

What are the key market segments in the industry?

Based on Vaccine Type, the Swine Vaccines Market is segmented into Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, and Recombinant Vaccines.  The Inactivated Vaccines are leading the market because they are not made with live pathogens which prevents their use from spreading disease to pigs, they are used by many scientists. Many choose them as they are stable, easy to store and control a variety of diseases in pigs. In commercial pig farms, where health is very important, both farmers and veterinarians often rely on inactivated vaccines to prevent repeated outbreaks in swine. For this reason, people in every region find railway systems to be attractive.

Based on Disease Target, the Swine Vaccines Market is segmented into Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), Classical Swine Fever (CSF), Foot and Mouth Disease (FMD), Swine Influenza, Mycoplasma Hyopneumoniae, and Others. In particular, the PRRS niche is leading the market at present. PRRS is considered a major cause of economic problems in the pig industry due to it affecting the reproductive system of breeding pigs and the respiratory systems of young pigs. The fast and widespread nature of PRRS has resulted in high numbers of targeted vaccines being sold. That is why extensive research and development focus on PRRS vaccines has led to the strongest contribution of the vaccination program segment to the whole swine vaccine market.

Which regions are leading the market, and why?

North American swine vaccines market is leading due to technologically advanced animal health care facilities, highly educated hog farmers and strict regulations. For large commercial pig operations in Canada and the United States, swine vaccines bank on maintaining their herd's health. For this market, there are biosecurity measures and regular vaccination programs to prevent PRRS and swine flu. Large animal health firms fuel market growth through expenditure on research and development innovations. Government initiatives for protecting the health of animals and the prevention of zoonotic diseases promote the steady use of advanced vaccine technologies in North America.

Given the increased interest in pork and Disease outbreaks in Vietnam, India, China and the Philippines increasing in frequency, the market for swine vaccines in the Asia-Pacific region is witnessing growth at a fast pace. As a result of regular outbreaks of classical swine fever and foot and mouth disease, governments and farmers are shifting towards actively vaccinating animals. Animal healthcare is becoming readily available to the population in the area and more awareness of animal health is being established. Because the area offers both a large swine population and a profitable market, corporations are investing in it to produce vaccines. As farming improves and security tightens, the use of swine vaccines is expected to grow significantly in Asia-Pacific.

What does the competitive landscape of the market look like?

In Swine Vaccines Market, several international and regional businesses focus on new products, developing vaccines for certain diseases and working together on strategies. Zoetis, Merck Animal Health, Boehringer Ingelheim, Ceva Santé Animale and Elanco Animal Health are among the leading companies that make and offer many vaccines against major swine diseases such as PRRS, PCV2 and swine influenza. They invest a lot in developing vaccines and try to ensure they remain safe and effective for a long time. Emerging countries are seeing local manufacturers make more vaccines for their communities, making the market more competitive. When veterinarian organizations and public agencies partner, new ideas emerge, driving innovation and allowing the market to prosper.

Swine Vaccines Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the industry?

• In September 2024, the EMA gave Merck & Co., Inc. marketing approval for PORCILIS PCV M Hyo ID, an intradermal vaccine meant for swine. This helps achieve good pig health and assists in expanding the pig farming market.
• In July 2024, South Africa, in collaboration with the FDA and DA BAI, approved the country’s first ASF vaccine to support the pork industry and ensure the safety of meat products.

Report Coverage:

By Vaccine Type

• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• DNA Vaccines
• Recombinant Vaccines

By Disease Target

• Porcine Reproductive and Respiratory Syndrome (PRRS)
• Porcine Circovirus Type 2 (PCV2)
• Classical Swine Fever (CSF)
• Foot and Mouth Disease (FMD)
• Swine Influenza
• Mycoplasma Hyopneumoniae
• Others

By Route of Administration

• Intramuscular
• Subcutaneous
• Intranasal
• Oral

By Application

• Commodity Pigs
• Breeding Pigs

By Distribution Channel

• Veterinary Hospitals & Clinics
• Veterinary Pharmacies
• Online Pharmacies
• Government Tenders
• Market Sales

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Zoetis Inc.
• Merck & Co., Inc.
• Boehringer Ingelheim International GmbH
• Ceva Santé Animale
• Elanco Animal Health Incorporated
• Phibro Animal Health Corporation
• HIPRA S.A.
• Virbac S.A.
• Indian Immunologicals Ltd.
• Vetoquinol S.A.
• Biogénesis Bagó
• Ringpu Biology Pharmaceutical Co., Ltd.
• Jinyu Bio-Technology Co., Ltd.
• Avimex Laboratory
• Zoetis Biodevices Pvt. Ltd.

Frequently Asked Questions (FAQs)